8-KLeadership Changes

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Nov 20, 2008)

Filed November 20, 2008For Securities:REGN

Summary

This 8-K filing from Regeneron Pharmaceuticals, Inc. (REGN) details amendments to its Change in Control Severance Plan and the employment agreement of its CEO, Dr. Leonard Schleifer. The primary driver for these changes is to ensure compliance with Section 409A of the Internal Revenue Code, which governs non-qualified deferred compensation arrangements and can impact severance benefits. Key modifications include aligning the definition of "Good Reason" within the severance plan to meet Section 409A requirements. Additionally, the ability for the company to pay cash in lieu of benefit continuation under the severance plan has been removed. For Dr. Schleifer's employment agreement, severance payments will now always be made in a lump sum, with potential delays to comply with Section 409A regulations. The company has also committed to indemnifying Dr. Schleifer against any violations of Section 409A related to his employment agreement.

Key Highlights

  • 1Regeneron amended and restated its Change in Control Severance Plan to comply with Section 409A of the Internal Revenue Code.
  • 2The definition of "Good Reason" in the severance plan was updated to align with Section 409A.
  • 3The company removed its ability to pay cash in lieu of benefit continuation under the severance plan.
  • 4Dr. Leonard Schleifer's employment agreement was amended and restated to comply with Section 409A.
  • 5Severance payments under Dr. Schleifer's agreement will now be made in a lump sum.
  • 6Potential six-month delay in severance payments for Dr. Schleifer if required by Section 409A.
  • 7Regeneron will indemnify Dr. Schleifer for any Section 409A violations related to his employment agreement.

Frequently Asked Questions

The primary reason for these amendments was to ensure compliance with Section 409A of the Internal Revenue Code, which imposes strict rules on non-qualified deferred compensation arrangements, including severance benefits. Failure to comply can result in significant tax penalties for the individual.

The definition of "Good Reason" was revised to better align with Section 409A, and the company can no longer pay cash in lieu of benefit continuation. These are technical adjustments to meet regulatory requirements.

Severance payments to Dr. Schleifer will now consistently be paid as a lump sum. There is also a provision for a potential delay of up to six months following his termination if Section 409A dictates it, ensuring compliance with the tax code. The company has also agreed to indemnify him against any 409A violations stemming from his employment agreement.

These are primarily technical, compliance-driven changes aimed at avoiding potential tax penalties for executives. For the company, it ensures its compensation plans are structured in a legally compliant manner, mitigating risks. For Dr. Schleifer, the lump-sum payment structure and the indemnity provision offer clarity and protection.